FibroBiologics Reports Durable Psoriasis Immunomodulation Data at SID 2026
HOUSTON, May 22, 2026 FibroBiologics, Inc. announced new preclinical data from its CYPS317 psoriasis program demonstrating durable immune modulation...
Fibroblast Therapy
Advertisement
Advertisement
